CD43(Bra7G), 0.2mg/mL [26628-22-8]

Biotium

CD43(Bra7G), 0.2mg/mL [26628-22-8]

9

Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

26628-22-8

Research Use Only

Monoclonal

Bra7G

0.2 mg/ml

SPN

sialophorin

CD43, GALGP, GPL115, LEU-22, LSN, leukosialin, galactoglycoprotein, leukocyte sialoglycoprotein, sialophorin (gpL115, leukosialin, CD43)

Mouse

IgM

Leukosialin

This antibody recognizes a cell surface glycoprotein of 95/115/135 kDa (depending upon the extent of glycosylation), identified as CD43 (Workshop V). Epitope of MAb Bra7G is clearly different from that of MAb DF-T1, called b as opposed to a for DF-T1. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma. This antibody is available purified with BSA/azide at 200 ug/mL, or BSA/azide-free at 1 mg/mL.

Animal

Bovine, Human, Mouse

2°C to 8°C,RT

41116161